Nephrol Dial Transplant (2002) 17: 29-36
© 2002 European Renal Association-European Dialysis and Transplant Association
Left ventricular alterations and end-stage renal disease
Centre Hospitalier FH MANHES, Fleury-Mérogis, France
Abstract
The prevalence of left ventricular (LV) changes, especially LV hypertrophy (LVH), is high among patients with chronic kidney disease and end-stage renal disease (ESRD). Ventricular enlargement usually is associated with normal systolic function and increased stroke and cardiac index. In the absence of intrinsic heart disease, LV enlargement is most probably attributable to chronic volume/flow overload associated with anaemia, the presence of arteriovenous shunts, and sodium and water retention. In ESRD patients, hypertension is also a leading cause of LVH, but structural LV changes and myocardial fibrosis may also be due to non-haemodynamic factors such as angiotensin II, parathyroid hormone, endothelin, aldosterone, increased sympathetic nerve discharge and increased plasma catecholamines. To improve the clinical outcomes in ESRD, it is essential to prevent LVH and its complications by correcting the factors that contribute to flow and pressure overload, including anaemia.
Keywords: anaemia; cardiac disease; haemodynamic factors; hypertension; kidney disease; left ventricular hypertrophy
Notes
Correspondence and offprint requests to: Gerard M. London, Centre Hospitalier FH MANHES, 8 Grande Rue, Fleury-Mérogis, 91700, France. Tel: +33169256485, fax: +33169461319, e-mail: glondon{at}club\|[hyphen]\|internet.fr
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
O. K. Chun, S.-J. Chung, K. J. Claycombe, and W. O. Song Serum C-Reactive Protein Concentrations Are Inversely Associated with Dietary Flavonoid Intake in U.S. Adults J. Nutr., April 1, 2008; 138(4): 753 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Basile, C. Lomonte, L. Vernaglione, F. Casucci, M. Antonelli, and N. Losurdo The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2008; 23(1): 282 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Verma, N. S. Anavekar, A. Meris, J. J. Thune, J. M. O. Arnold, J. K. Ghali, E. J. Velazquez, J. J.V. McMurray, M. A. Pfeffer, and S. D. Solomon The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction: The VALIANT Echo Study J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1238 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bayes, M. C. Pastor, J. Bonal, A. Foraster, and R. Romero Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up Nephrol. Dial. Transplant., April 1, 2006; 21(4): 984 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Schreiber Levocarnitine and Dialysis: A Review Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243. [Abstract] [Full Text] [PDF] |
||||



